Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Influenza virus vaccine - Dynavax

Drug Profile

Influenza virus vaccine - Dynavax

Alternative Names: Me2 ISS + NP ISS; N 8295; Universal flu vaccine (M2e/NP-ISS + trivalent influenza vaccine) - Dynavax; Universal flu vaccine - Dynavax

Latest Information Update: 16 Oct 2013

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Dynavax Technologies
  • Class Influenza virus vaccines
  • Mechanism of Action Immunostimulants; Toll-like receptor 9 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Influenza virus infections

Most Recent Events

  • 16 Oct 2013 No development reported - Phase-I for Influenza virus infections (prevention) in USA (IM)
  • 18 Apr 2012 Phase-I development is ongoing USA
  • 07 Dec 2010 Adverse events and immunogenicity data from a phase Ia trial released by Dynavax
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top